{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:21Z","timestamp":1792839861111,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>AQP4-IgG has been considered as the pathogenic factor leading to NMOSD. However, about 20\u201330% of patients lack AQP4-IgG. So far, all therapeutic medicines are ineffective for NMOSD patients without AQP4 IgG. Thus AQP4-IgG is the pathogenic factor of NMOSD has been suspected and challenged. In addition, lack of efficacy of immunotherapy in NMOSD without AQP4 IgG has been a serious problem in the neurology. Identifying the clinical and laboratory characteristics and diversities between NMOSD patients with and without AQP4-IgG can be helpful to further explore the pathogenesis of NMOSD and guide clinical treatment. This is a single-centre retrospective study in The First Hospital of Jilin University, China including 92 patients diagnosed as NMOSD from January 2013 to January 2015. The characteristics of clinic, blood, cerebrospinal fluid (CSF), and image between AQP4-IgG negative (AQP4-IgG\u2212) and AQP4-IgG positive (AQP4-IgG+) NMOSDs were compared. Our results showed that in the AQP4-IgG+ group, the ratio of women to men was 5.55, while in AQP4-IgG\u2212 group was 1.54 (P = 0.0092). In the AQP4-IgG+ patients, the expanded disability status scale (EDSS) was from 0 to 8.5, with an average of 5.550 \u00b1 0.25, and the AQP4-IgG\u2212 patients had the EDSS score from 0 to 9, with an average of 4.032 \u00b1 0.36 (P = 0.0006), which mainly affected movement system (P &amp;lt; 0.05) and superficial sensory impairment (P &amp;lt; 0.05). In the AQP4-IgG+ group, the blood brain barrier (BBB) permeability (P = 0.0210) and myelin basic protein (MBP) were increased (P = 0.0310) when compared to AQP4-IgG\u2212 group. Higher level IL-17 was seen in AQP4-IgG+ group than AQP4-IgG\u2212 group (P= 0.0066). Our results demonstrated that the NMOSD with AQP4-IgG more likely occurred in women and presented more severe clinical symptoms as well as significant BBB damage and increased MBP and IL-17 in CSF and blood, respectively compared with NMOSD without AQP4-IgG group. The differences in clinical and laboratory profiles between NMOSD with and without AQP4-IgG indicate the heterogeneity of NMOSD, in which AQP4-IgG may not be the only pathogenic molecule. It is necessary to find more pathogenic factors and to explore the new pathogenesis of NMOSD and therapeutic methods in the future.<\/jats:p>","DOI":"10.1093\/cei\/uxad053","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:08:53Z","timestamp":1683763733000},"page":"363-370","source":"Crossref","is-referenced-by-count":16,"title":["Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?"],"prefix":"10.1093","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-1768","authenticated-orcid":false,"given":"Fengna","family":"Chu","sequence":"first","affiliation":[{"name":"Neuroscience Center, Department of Neurology, The First Hospital of Jilin University , Changchun , China"},{"name":"Department of Neurobiology, Care Sciences & Society, Division of Neurogeriatrics, Karolinska Institutet, Karolinska University Hospital Solna , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Shi","sequence":"additional","affiliation":[{"name":"Neuroscience Center, Department of Neurology, The First Hospital of Jilin University , Changchun , China"},{"name":"Department of Neurobiology, Care Sciences & Society, Division of Neurogeriatrics, Karolinska Institutet, Karolinska University Hospital Solna , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Neuroscience Center, Department of Neurology, The First Hospital of Jilin University , Changchun , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[{"name":"Neuroscience Center, Department of Neurology, The First Hospital of Jilin University , Changchun , China"},{"name":"Department of Neurobiology, Care Sciences & Society, Division of Neurogeriatrics, Karolinska Institutet, Karolinska University Hospital Solna , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2023101309425837900_CIT0001","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.4103\/0972-2327.164816","article-title":"Neuromyelitis optica spectrum disorders: an update","volume":"18","author":"Pandit","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"2023101309425837900_CIT0002","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"2023101309425837900_CIT0003","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"2023101309425837900_CIT0004","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O\u2019Connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023101309425837900_CIT0005","doi-asserted-by":"crossref","first-page":"635419","DOI":"10.3389\/fneur.2021.635419","article-title":"Anti-aquaporin 4 IgG is not associated with any clinical disease characteristics in neuromyelitis optica spectrum disorder","volume":"12","author":"Schmetzer","year":"2021","journal-title":"Front Neurol"},{"key":"2023101309425837900_CIT0006","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"2023101309425837900_CIT0007","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sepulveda","year":"2018","journal-title":"Mult Scler"},{"key":"2023101309425837900_CIT0008","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"2023101309425837900_CIT0009","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.0000000000002655","article-title":"Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder","volume":"86","author":"Hyun","year":"2016","journal-title":"Neurology"},{"key":"2023101309425837900_CIT0010","doi-asserted-by":"crossref","first-page":"577506","DOI":"10.1016\/j.jneuroim.2021.577506","article-title":"The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: experience with 461 cases from a single centre in South China","volume":"353","author":"Li","year":"2021","journal-title":"J Neuroimmunol"},{"key":"2023101309425837900_CIT0011","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"89","author":"Jarius","year":"2018","journal-title":"Nervenarzt"},{"key":"2023101309425837900_CIT0012","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-94-024-1057-0_16","article-title":"Aquaporin-targeted therapeutics: state-of-the-field","volume":"969","author":"Tradtrantip","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2023101309425837900_CIT0013","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1212\/NXI.0000000000000727","article-title":"Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD","volume":"7","author":"Jitprapaikulsan","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023101309425837900_CIT0014","doi-asserted-by":"crossref","first-page":"e759","DOI":"10.1212\/NXI.0000000000000759","article-title":"Are aquaporin antibody titers useful outcome measures for neuromyelitis optica spectrum disorders","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023101309425837900_CIT0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"2023101309425837900_CIT0016","doi-asserted-by":"crossref","first-page":"102921","DOI":"10.1016\/j.autrev.2021.102921","article-title":"Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges","volume":"21","author":"Liu","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2023101309425837900_CIT0017","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2017.04.001","article-title":"Expansion of IL-6(+) Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients","volume":"307","author":"Barros","year":"2017","journal-title":"J Neuroimmunol"},{"key":"2023101309425837900_CIT0018","doi-asserted-by":"crossref","first-page":"105793","DOI":"10.1016\/j.intimp.2019.105793","article-title":"Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: a meta-analysis","volume":"75","author":"Hou","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2023101309425837900_CIT0019","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1212\/WNL.0000000000010789","article-title":"Unraveling B lymphocytes in CNS inflammatory diseases: distinct mechanisms and treatment targets","volume":"95","author":"Klein da Costa","year":"2020","journal-title":"Neurology"},{"key":"2023101309425837900_CIT0020","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fneur.2018.00648","article-title":"Blood brain barrier permeability could be a biomarker to predict severity of neuromyelitis optica spectrum disorders: a retrospective analysis","volume":"9","author":"Wang","year":"2018","journal-title":"Front Neurol"},{"key":"2023101309425837900_CIT0021","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult Scler"},{"key":"2023101309425837900_CIT0022","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/brain\/awab102","article-title":"Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders","volume":"144","author":"Takai","year":"2021","journal-title":"Brain"},{"key":"2023101309425837900_CIT0023","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J Neurol"},{"key":"2023101309425837900_CIT0024","doi-asserted-by":"crossref","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"key":"2023101309425837900_CIT0025","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"2023101309425837900_CIT0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"2023101309425837900_CIT0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2017.11.004","article-title":"Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: a cohort of Latin American patients","volume":"19","author":"Carnero Contentti","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2023101309425837900_CIT0028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/0004-282x20160193","article-title":"Neuromyelitis optica: phenotypic characteristics in a Brazilian case series","volume":"75","author":"Del Negro","year":"2017","journal-title":"Arq Neuropsiquiatr"},{"key":"2023101309425837900_CIT0029","doi-asserted-by":"crossref","first-page":"102208","DOI":"10.1016\/j.msard.2020.102208","article-title":"Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort","volume":"44","author":"Edgar Patricio","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2023101309425837900_CIT0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative international research in clinical and longitudinal experience study in NMOSD","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023101309425837900_CIT0031","first-page":"60","article-title":"Neuromyelitis optica","volume":"79","author":"Ferr\u00e1n","year":"2019","journal-title":"Medicina"},{"key":"2023101309425837900_CIT0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"2023101309425837900_CIT0033","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.msard.2021.102742","article-title":"What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)","volume":"49","author":"Carnero Contentti","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2023101309425837900_CIT0034","doi-asserted-by":"crossref","first-page":"102718","DOI":"10.1016\/j.msard.2020.102718","article-title":"Anti-MOG associated disorder\u2014clinical and radiological characteristics compared to AQP4-IgG+ NMOSD\u2014a single-center experience","volume":"48","author":"Rempe","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2023101309425837900_CIT0035","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"2023101309425837900_CIT0036","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxad053\/50422681\/uxad053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/213\/3\/363\/52058466\/uxad053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/213\/3\/363\/52058466\/uxad053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T11:43:19Z","timestamp":1702381399000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/213\/3\/363\/7159114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,10]]},"published-print":{"date-parts":[[2023,10,13]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxad053","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,5,10]]}}}